Aurinia Pharmaceuticals (AUPH) Gross Profit (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Gross Profit data on file, last reported at $71.2 million in Q1 2026.

• Quarterly Gross Profit rose 32.12% year-over-year to $71.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.7 million (up 22.67% YoY) and the FY2025 annual result came in at $250.4 million, up 21.03% from the prior year.
• Gross Profit improved to $71.2 million in Q1 2026, from $68.3 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $71.2 million in Q1 2026 to a low of $21.4 million in Q1 2022.
• A 5-year average of $48.1 million and a median of $48.3 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit soared 2367.55% — and 2023, when it dropped 10.47%.
• Tracing AUPH's Gross Profit over 5 years: stood at $27.1 million in 2022, then jumped by 46.64% to $39.7 million in 2023, then surged by 36.81% to $54.3 million in 2024, then gained by 25.78% to $68.3 million in 2025, then grew by 4.22% to $71.2 million in 2026.
• The last three Gross Profit figures came in at $71.2 million (Q1 2026), $68.3 million (Q4 2025), and $65.3 million (Q3 2025), per Business Quant data.